Abstract
Peripheral neuropathies pose a peculiar challenge in assessing response to therapeutic interventions. Superficially, one would expect it to be a simple matter to assess the presence or lack of response to any intervention in peripheral neuropathies. After all, the peripheral nervous system is readily available to examination by both non-invasive and invasive tests. Experience has proved this to be a false expectation when dealing with chronic axonal neuropathies. For the most part, no therapy is available for these neuropathies. Generally, the elimination of cause (e.g. toxic drug) or minimisation of metabolic derangement (e.g. impaired glycaemic control) are the only therapies available for chronic neuropathies. As more therapeutic interventions are proposed (e.g. aldose reductase inhibitors in diabetic polyneuropathy, nerve growth factor for small-fibre neuropathies), accurate methods of assessing response are essential. In the case of autoimmune neuropathies — e.g. acute inflammatory demyelinating polyneuropathy (AIDP), chronic inflammatory demyelinating polyneuropathy (CIDP) — positive clinical and electrophysiological therapeutic responses are shown more readily, and successful therapies are available.
Chapter PDF
References
Hughes R, Newsom-Davis J, Perkin G, Pierce J. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978; II: 750–753.
Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096 1104.
Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225–229.
Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993; 341: 586–590.
Cornblath D, Mellitts E, Griffin J, McKhann GM, Albers JW, Miller RG, et al. Motor conduction studies in Guillain-Barré syndrome: description and prognostic value. Ann Neurol 1988; 23: 354–359.
Hughes R. Ineffectiveness of high-dose intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1991; 338: 1142.
Hahn A, Bolton C, Pillay N, Chalk C, Benstead T, Bril V, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. Brain 1996; 119: 1055–1066.
Dyck P, Litchy W, Kratz K, Suarez G, Low P, Pineda A, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36: 838–845.
Britland S, Young R, Sharma A, Clarke B. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. Diabetes 1990; 39: 898–908.
Ochoa J. Positive sensory symptoms in neuropathy: mechanisms and aspects of treatment. In: Asbury A, Thomas P, editors. Peripheral nerve disorders 2. Oxford: Butterworth-Heinemann, 1995: 44–58.
Dyck P. Quantitating severity of neuropathy. In: Dyck P, Thomas P, Griffin J, Low P, Poduslo J, editors. Peripheral neuropathy. Philadelphia: Saunders, 1993: 685–697.
Sima A, Bril V, Nathaniel V, McEwen T, Brown M, Lattimer S, et al. Regeneration and repair of myelinated fibers in sural nerve biopsies from patients with diabetic neuropathy treated with sorbinil, an investigational aldose reductase inhibitor. N Engl J Med 1988; 319: 548–555.
Green DA, Arezzo JC, Brown MD. The Zenarestat Study Group, Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 1999; 53: 580–591.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.
Arezzo J. The use of electrophysiology for the assessment of diabetic neuropathy. Neurosci Res Commun 1997; 21: 13–23.
Bril V. Role of electrophysiological studies in diabetic neuropathy. Can J Neurol Sci 1994; 21: S8 - S12.
Daube J. Electrophysiologic Testing in diabetic neuropathy. In: Dyck P, Thomas P, Asbury A, Winegrad A, Porte DJ, editors. Diabetic Neuropathy. Philadelphia: Saunders, 1987; 162–176.
Lamontagne A, Buchthal G. Electrophysiological studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 1970; 33: 442–452.
Macleod A, Till S, Sonksen P. Discussion of the clinical trials of the aldose reductase inhibitor, tolrestat. Int Proc J 1991; 4: 17–24.
Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991; 41: 617–618.
Peripheral Nerve Society. Diabetic polyneuropathy in controlled clinical trials: consensus report of the peripheral nerve society. Ann Neurol 1995; 38: 478–482.
Consensus Statement of the American Diabetes Association and the American Academy of Neurology. Report and re-
commendations of the San Antonio conference on diabetic neuropathy. Diabetes 1988; 37: 1000–1004.
Consensus Statement. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Neurology 1992; 42: 1823–1829.
Bril V, Ellison R, Ngo M, Bergstrom B, Raynard D, Gin H, Roche Neuropathy Study Group. Electrophysiological monitoring in clinical trials. Muscle Nerve 1998; 21: 1348–1393.
Judzewitsch R, Jaspan J, Polonsky K, Weinberg C, Halter J, Halar E, et al. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 1983; 308: 119–125.
Macleod A, Boulton A, Owens D, Van Rooy P, Van Gerven JM, Macrury S, et al. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic peripheral neuropathy. Diabete Metab 1992; 18: 14–20.
Malone JI, Lowitt S, Korthals JK, Salem A, Miranda C. The effect of hyperglycemia on nerve conduction and structure is age dependent. Diabetes 1996; 45: 209–215.
Reichard P, Nilsson B, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of micro-vascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304–309.
Service F, Rizza R, Daube J, O’Brien P, Dyck P. Near normoglycaemia improved nerve conduction and vibration sensation in diabetic neuropathy. Diabetologia 1985; 28: 722–727.
Troni W, Carta Q, Cantello R, Caselle MT, Rainero I. Peripheral nerve function and metabolic control in diabetes mellitus. Ann Neurol 1984; 16: 178–183.
Young R, Ewing D, Clarke B. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 1983; 32: 938–942.
Arezzo J, Schaumburg J, Petersen C. Rapid screening for peripheral neuropathy: a field study with the Optacon. Neurology 1983; 33: 626–629.
Brit V, Kojic J, Ngo M, Clark K. Comparison of a Neurothesiometer and Vibratron in measuring vibration perception thresholds and relationship to nerve conduction studies. Diabetes Care 1997; 20: 1360–1362.
Yarnitsky D. Quantitative sensory testing. Muscle Nerve 1997; 20: 198–204.
Ewing D, Campbell I, Clarke B. The natural history of diabetic autonomic neuropathy. Am J Med 1980; 49: 95–108.
Rathmann W, Ziegler D, Jahnke M, Haastert B, Gries F. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993; 10: 820–824.
Low P. Pitfalls in autonomic testing. In: Low P, editor. Clinical autonomic disorders: evaluation and management. Boston: Little, Brown, 1993: 355–365.
Low P, Pfeifer M. Standardization of clinical tests for practice and clinical trials. In: Low P, editor. Clinical autonomic disorders: evaluation and management. Boston: Little, Brown, 1993: 287–296.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag London
About this chapter
Cite this chapter
Bril, V. (2001). Peripheral Neuropathies: Experience with Large Multicentre Trials. In: Guiloff, R.J. (eds) Clinical Trials in Neurology. Springer, London. https://doi.org/10.1007/978-1-4471-3787-0_37
Download citation
DOI: https://doi.org/10.1007/978-1-4471-3787-0_37
Publisher Name: Springer, London
Print ISBN: 978-1-84996-856-0
Online ISBN: 978-1-4471-3787-0
eBook Packages: Springer Book Archive